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Cardiac resynchronization therapy is an effective therapy for patients with left ventricular systolic
dysfunction and a ventricular conduction delay; however, approximately 30% of patients do not
experience signiﬁcant clinical improvement with this treatment. Modern devices allow individualized
programming of the AV delay and VV offset, which offer the possibility of improving clinical response
rates with optimized programming. AV and VV delay optimization techniques have included
echocardiography, device-based algorithms, and several other novel noninvasive techniques. While
an acute improvement in hemodynamic function has been clearly demonstrated with optimized device
settings, long-term clinical beneﬁt is limited. In the majority of cases, an empiric AV delay with
simultaneous biventricular or left ventricular pacing is adequate. The value of optimization of these
intervals in ‘‘non-responders’’ still requires further investigation.
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Cardiac resynchronization therapy (CRT) has become an
important treatment for the management of heart failure (HF)
patients with left ventricular (LV) systolic dysfunction and a
ventricular conduction delay [1,2]. Multiple randomized studies
have demonstrated improvements in symptoms and cardiac
function as well as reductions in morbidity and mortality inrt Rhythm Society. Published by E
: þ1 843 876 4990.appropriately selected patients with moderate to severe HF
despite optimal medical therapy [3–7]. More recent studies have
also demonstrated beneﬁt in patients with milder forms of HF,
which has expanded the population eligible for device-based
therapy [8–10]. A response to CRT is not guaranteed, as approxi-
mately 30% of patients do not appear to experience signiﬁcant
clinical improvement [11]. This proportion of non-responders
varies with the measure used, but clearly there is an opportunity
to improve the effectiveness of this therapy. Given the inherent
risks and costs of device implantation and maintenance, a reduc-
tion in the rate of CRT ‘‘non-responders’’ is an important goal.lsevier B.V. All rights reserved.
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two available strategies that can potentially increase the proportion
of patients who respond to CRT. With regard to the former,
measures of mechanical dyssynchrony to select patients have been
disappointing. Indeed, the multicenter PROSPECT trial failed to
identify any single echocardiographic marker of dyssynchrony that
was predictive of response to CRT [11]. There are other promising
techniques such as pacing at sites of late mechanical or electrical
activation, and avoiding pacing in patients with signiﬁcant left
ventricular scar.
Device optimization post-implantation includes individualized
programming of the atrioventricular (AV) and ventriculo-ventricular
(VV) delay to maximize the hemodynamic and, hopefully, clinical
response to CRT. While early CRT devices allowed AV delay program-
ming with simultaneous biventricular (BiV) pacing, modern systems
allow programming of both the individual AV and VV intervals.
Considering additional variables such as the AV delay offset for atrial-
sensed (AS) vs. atrial-paced (AP) CRT and rate-adaptive AV delay
modulation, the complexity of CRT programming is obvious. There
are multiple strategies for AV and VV optimization without a clear
‘‘gold standard’’ for comparison, which makes interpretation of
available data challenging. Guidelines for CRT also do not provide
recommendations for optimization of these parameters, reﬂecting a
lack of consensus on this issue [1,2]. Despite these limitations, AV and
VV optimization may prove useful in select patients with CRT, and a
working understanding of the methods and controversies involved is
important for all physicians who manage these patients.2. AV optimization
The importance of AV synchrony is intuitive, as preservation of
both passive and active LV ﬁlling contribute to stroke volume and
cardiac output. Interestingly, AV optimization may be more useful
to resynchronize the left ventricle electrically than to optimize
ﬁlling. Early studies in patients with complete heart block and
dual chamber pacemakers conﬁrmed variation in stroke volume
with changes in programmed AV delay [12]. In CRT, in which the
majority of patients have preserved intrinsic AV nodal conduction
but prolonged inter- and intraventricular conduction, AV delay
programming has also been correlated with changes in LV systolic
function, as measured invasively by dP/dt [13]. As a result,
methods of AV delay optimization have been the focus of
numerous studies using approaches that focus on optimization
of either LV diastolic or systolic function, primarily through use of
Doppler echocardiography (Fig. 1). Furthermore, all of the major
trials of CRT in HF patients, with the exception of the CONTAK-CD
trial [4], performed some method of AV delay optimization.Fig. 1. Doppler optimization of AV delay. AV delay optimization techniques have
focused on optimizing either left ventricular diastolic (mitral inﬂow) or systolic
(aortic outﬂow) function.2.1. Optimizing LV diastolic ﬁlling
AV delay optimization based on LV diastolic function utilizes
the ﬁlling pattern obtained through Doppler echocardiography of
mitral inﬂow, and several different methods have been used and
evaluated. Mitral inﬂow is dependent on timing of both left atrial
and left ventricular systole, and interatrial and interventricular
conduction delays will affect optimal timing of ventricular pacing.
A relatively short AV delay may result in truncation of the A wave,
representing atrial systole, while a prolonged AV delay can also
result in shortening of total diastolic ﬁlling time (Fig. 2) [14]. One
of the earliest and more commonly cited methods of AV delay
optimization using mitral inﬂow is the Ritter method. Originally
validated in patients with dual chamber pacemakers, and heart
block the Ritter method involves measuring the interval from the
QRS onset or pacing spike to the end of the A wave at relatively
long and short AV delays, and the difference between these two is
subtracted from the ‘‘long’’ AV delay to arrive at the optimal AV
delay (Fig. 3). This formula is intended to result in optimal
diastolic ﬁlling time without truncation of the A wave. AV delays
derived using this method have been shown to correlate with
improvements in stroke volume (derived from impedance cardio-
graphy) in comparison to nominal AV delays in patients with dual
chamber pacemakers [12]. This was method of AV optimization
used in the InSync III trial [15].
Other strategies utilizing the mitral inﬂow pattern include a
‘‘fast and simple’’ approach and the iterative method. The ‘‘fast
and simple’’ method requires the presence of mitral regurgitation
on the spectral Doppler pattern. The AV delay is set 5–10 ms
below the longest AV delay ensuring biventricular capture. The
time interval from the end of the A wave to the onset of high
velocity mitral regurgitation (i.e., LV contraction) is subtracted
from the long AV delay to arrive at the optimal AV delay. The
optimal AV delay derived with this method has been shown to
result in higher invasively measured cardiac output [16].
The iterative method is the most common echocardiographic
optimization technique; this was used in the CARE-HF [7] and the
SMART-AV [17] trials and involves programming a relatively long
AV interval with gradual shortening in 20 ms steps. When
truncation of the A wave is observed on the mitral inﬂow Doppler,
the AV interval is gradually prolonged in 10 ms steps until the
delay with maximal E and A wave separation is obtained (Fig. 4).
However, use of this method did not result in improved clinical or
echocardiographic outcomes over a nominal, ﬁxed AV delay in
CRT patients in the SMART-AV trial, as will be discussed later [17].
More recently, the reproducibility and consistency of measure-
ment of this technique has been challenged despite its relative
ease of use compared with other techniques [18].
2.2. Optimizing LV systolic performance
Doppler-derived measures of left ventricular systolic function
have also been applied to AV delay optimization. In a study by
Morales et al. [19], a ﬁxed AV delay of 120 ms was compared to a
strategy of AV delay optimization by Doppler estimation of LV
dP/dt from the mitral regurgitant jet. While the study included
only 26 patients, those who were optimized experienced more
6-month improvement in New York Heart Association (NYHA)
class and ejection fraction than those with a ﬁxed AV delay.
Similar to the ‘‘fast and simple’’ method described above, this
method is limited by the requirement for a well-deﬁned mitral
regurgitant jet.
AV delay has also been optimized through evaluation of the
aortic pulsed-wave Doppler velocity time integral (VTI), as this
has been shown to correlate with LV stroke volume [20]. Using
this method, aortic VTI is measured over a range of AV delays, and
Fig. 2. Effect of AV delay on Mitral Inﬂow. AV delays that are either too short (A) or too long (C) will result in truncation of the A wave of mitral inﬂow or E and A wave
fusion, respectively. At the optimal AV delay, E and A wave separation results in maximum diastolic ﬁlling time without truncation of the A wave.
Fig. 3. The Ritter Method. The interval from the pacing spike to the end of the A wave on mitral inﬂow is measured at short and long AV delays. The difference in these
time intervals is then subtracted from the long AV delay to calculate the optimal AV delay.
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the optimal AV delay (Fig. 5). In two small, nonrandomized
comparisons of AV delay optimization by the aortic VTI method
vs. the Ritter method of mitral inﬂow, optimization by VTI was
shown to result in a higher VTI [21,22]. This method was also
compared with a ﬁxed AV delay in a randomized study of 40
patients. Patients optimized using aortic VTI experienced greater
3-month improvement in NYHA class and quality of life. Impor-
tantly, they also reported stable optimal AV delays over time [23].
Mitral inﬂow VTI is another method of Doppler optimization of
the AV delay. In a study of 30 patients undergoing CRT implanta-
tion, AV delay was optimized based on the maximal increase in
invasively measured left ventricular dP/dt and compared with
those derived from the maximal increase in mitral inﬂow E and A
wave VTI, the iterative method, aortic VTI, and Ritter formula.
These investigators found that the AV delay optimized using themitral inﬂow VTI correlated best with the maximal increase in
dP/dt (29 of 30 patients), while that derived from Ritter’s formula
showed no concordance [24].
2.3. Other methods of AV optimization
The above methods for AV delay optimization all rely on
echocardiography. While this has been the ‘‘gold standard’’ for
AV delay optimization, it requires signiﬁcant training, skill, time,
and healthcare resources. As a result, several alternative non-
invasive tools have been developed for AV delay optimization. In
general, these include noninvasive measures of hemodynamic
optimization and device-based intracardiac electrogram (IEGM)
algorithms. Impedance cardiography (IC), for example, uses
changes in transthoracic impedance to estimate stroke volume
[12]. In a study of 24 patients following CRT implantation, AV
Fig. 4. The iterative method. Without pacing there is fusion of the E and A waves on mitral inﬂow. The AV delay is then gradually shortened, resulting in increased E and A
wave separation until A wave truncation becomes apparent at a delay of 60 ms. The delay can then be prolonged in 10 ms steps to achieve maximal separation.
Fig. 5. Aortic VTI method. AV delay optimized to achieve the maximum stroke volume based on the aortic outﬂow tract VTI. In this case, the VTI increased from 16 to
23 cm with an increase in the AV delay from 80 to 150 ms. This can also be used in VV interval optimization (see text for details).
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volume was comparable to that that derived from the aortic VTI
method (o20 ms difference in predicted AV delay in 88%) [25].
Finger photoplethysmography (FPPG) is an alternative non-
invasive tool for hemodynamic assessment during AV delay opti-
mization. FFPG allows measurement of changes in peripheral pulse
pressure, which was observed to correlate reasonably well with
simultaneously measured central aortic pressure in 57 patients
undergoing CRT [26]. In this group, the optimal AV delay, deﬁned
as that producing the greatest change in pulse pressure, was
identical using either FFPG or central aortic pressure. Similarly, the
Finometers (Finapres Medical Systems, Amsterdam, Holland) is a
device that provides continuous, noninvasive measurement of
arterial pressure through a ﬁnger cuff photoelectric plethysomgraph.
In an initial study of 12 patients with CRT, this device predicted the
optimal AV delay based on maximal increase in pulse pressure
within 40 ms of that derived from aortic VTI [27].
Peak endocardial acceleration (PEA) is a device-based algo-
rithm that has also been evaluated for AV delay optimization. The
algorithm makes use of an accelerometer incorporated into a
pacing lead behind the pacing electrode, and it has been shown tocorrelate well with the optimal AV delay by the Ritter method in
patients with dual chamber pacemakers and heart block [28,29].
More recently, the PEA algorithm was evaluated for AV and VV
optimization in CRT patients. The CLEAR trial randomized 238
patients with CRT to PEA optimized AV/VV intervals or to ‘‘usual’’
optimization methods. At one-year follow-up, response to CRT
was signiﬁcantly higher in the group optimized by PEA (76 vs.
62%), although this beneﬁt was largely restricted to improve-
ments in subjective endpoints [30].
Finally, acoustic cardiography is another relatively new tech-
nique for AV optimization. This technology integrates the surface
electrocardiogram and heart sound data to measure the intensity
of S3, the electromechanical activation time (EMAT, representing
the time from the QRS onset to S1), and LV systolic time (LVST, the
time interval from S1 to S2). Changes in each parameter can
indicate worsening heart failure: an increase in S3 suggestive of
increased left ventricular ﬁlling pressure, prolongation of EMAT
indicative of reduced LV contractility, and a reduced LVST sug-
gestive of reduced systolic function. An AV delay tailored to
optimize these parameters in 22 CRT patients was comparable
to the mitral inﬂow method [31].
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IEGM-based AV delay algorithms are clearly desirable given
the potential for incorporation into device software for rapid
optimization and potentially continuous modiﬁcation. Such tech-
nology could reduce costs, time, and the possibility of user error
introduced with more complex methods such as echocardiography.
Investigators from the PATH-CHF studies derived an algorithm
based on the intrinsic AV delay and QRS width that accurately
predicted the AV delay resulting in maximum dP/dt [32], which
was subsequently used for AV delay programming in the COM-
PANION trial [5]. A further iteration of this algorithm (EEHFþ)
was later shown to be superior to aortic VTI and the Ritter method
for optimizing dP/dt in 28 patients undergoing CRT implantation
[33]. However, the pivotal SMART-AV trial ultimately cast doubt
on the utility of routinely using this IEGM-based algorithm
and AV delay optimization altogether. This trial randomized
980 patients with CRT to a ﬁxed AV delay of 120 ms, echocardio-
graphically optimized AV delay via the iterative method, or AV
delay programming using the SmartDelayTM algorithm (Boston
Scientiﬁc, Natik, Massachusetts, USA). At 6-month follow-up,
there were no signiﬁcant differences in improvement in left
ventricular volumes, ejection fraction, or clinical endpoints that
included 6-min walk distance, quality of life score, and NYHA
classiﬁcation [17].
2.5. Areas of uncertainty in AV optimization
It is evident that many issues regarding AV delay optimization
remain unresolved. While the majority of the landmark trials of
CRT incorporated some form of AV delay optimization at the time
of implantation, deﬁnitive data supporting their superiority over
an empiric, ﬁxed AV delay are lacking. Most available data involve
hemodynamic studies demonstrating an acute improvement with
optimization. More relevant, however, are long-term, rando-
mized, controlled studies of these interventions on clinical out-
comes. With the exception of SMART-AV, comparative studies
have been too small to draw meaningful conclusions. Indeed,
SMART-AV suggests that empiric programming of a ﬁxed AV
delay results in similar clinical outcomes to an optimized AV
delay, at least with the methods used in the trial. As this was a
study of optimized AV delay in all patients referred for CRT, the
results do not exclude the possibility of beneﬁt in certain
subgroups of patients such as CRT ‘‘non-responders.’’ One center,
for example, has reported a reduction in adverse events through
use of a CRT optimization clinic, in which device programming
modiﬁcation, including AV delay optimization, was deemed
necessary in 47% of CRT ‘‘non-responders’’ [34].
Other areas of uncertainty in AV delay programming include
the stability of the optimal AV delay, atrial paced/sensed offset,
and rate-adaptive AV delay. The majority of studies report the
acute hemodynamic effects of the optimal AV delay at implant or
shortly thereafter, with few evaluating the long-term stability of
the optimized AV delay. In three independent studies of AV delay
optimization using mitral inﬂow Doppler at enrollment, repeat
echocardiographically guided optimization at follow-up demon-
strated signiﬁcant differences from baseline values [35–37]. These
data suggest that the optimal AV delay is not constant and may in
part explain the lack of long-term clinical beneﬁt of optimization
over an empiric AV delay in SMART-AV. Furthermore, if optimiza-
tion is performed, the optimal timing and method remain
undeﬁned.
Early studies in CRT primarily enrolled chronotropically com-
petent patients with little need for atrial pacing. As a result,
device programming generally used a VDD pacing mode, with
predominant or exclusive atrial sensing. Given the prevalence ofboth intrinsic and iatrogenic sinus node dysfunction in heart
failure populations, atrial pacing is often clinically necessary and,
at times, desirable. The optimal AV delay offset with AP has been
shown to be patient speciﬁc and differ signiﬁcantly from nominal
device settings. In a comparison of IEGM AV delay optimization
versus conventional Doppler methods in 28 patients, the mean
optimized AP/AS offset was found to be 75 ms, and 88% of
patients had an offset greater than the nominal 30 ms of the
device. Atrial pacing also resulted in a signiﬁcantly higher LV
dP/dt in this population [33]. A subsequent study of optimized
AP/AS AV delays using dP/dt also demonstrated a 72 ms offset
to achieve maximal hemodynamic response. Interestingly, the
increase in dP/dt during AP was associated with reductions in
echocardiographic measures of LV ﬁlling and stroke volume [38].
These results suggest that if AV delay optimization is performed,
AS and AP AV delays should be determined individually. If not, an
empirical AP/AS offset of 60–70 ms is reasonable. The utility of
atrial support pacing in CRT has also been recently evaluated in
the PEGASUS CRT trial [39]. In this study, 1433 patients were
randomized to DDD40, DDD70, or DDDR40, with AV delay
programming using the SmartDelayTM algorithm. Atrial pacing
was more frequent in the DDD70 group (43%) than in the DDD40
(3%) or DDDR40 (4%), but there were no signiﬁcant differences in
mortality, heart failure events, NYHA functional class improve-
ment, or arrhythmic burden. Despite a lack of beneﬁt to atrial
support pacing, the absence of observed harm is of clinical
importance to safely allow such programming among patients
with chronotropic incompetence.
Rate-adaptive AV delay shortening algorithms are a universal
feature in modern dual chamber pacing systems due to improve-
ments in exercise capacity with their use [40], although the utility
of such an algorithm in CRT devices is controversial. One study of
36 patients determined the optimal AV delay during rapid atrial
pacing and following exercise using the aortic VTI method. The
optimal AV delay by VTI was paradoxically longer at faster heart
rates [41]. However, two recent studies have called this into
question. Raﬁe et al. [42] found that the optimal AV delay was
shorter at higher atrial pacing rates, and clinical improvement
was demonstrated with rate-adaptive AV delay programming.
Shanmugam et al. [43] performed AV delay optimization using
the iterative method in 52 patients at rest and with exercise and
found that the optimal AV delay was shorter at higher heart rates.
They also performed cardiopulmonary exercise testing in patients
randomized to a rate-adaptive AV delay algorithm programmed
on or off, and use of the algorithm resulted in signiﬁcantly longer
exercise times and higher peak oxygen consumption. While the
standard of care has been to disable this feature in CRT devices,
these data suggest that it may in fact be beneﬁcial. The RAVE
study evaluated atrioventricular times with exercise and atrial
pacing. This study will provide important data for the need for
dynamic AV delay programming with IEGM-based timing
algorithms.3. VV optimization
From the foregoing discussion, it is clear that AV delay
programming to ensure ventricular preexcitation with optimal
LV diastolic ﬁlling and systolic function is complex, and the
optimal method that translates into improved patient outcomes
is uncertain. These issues are even more apparent in studies of VV
optimization. The landmark trials of CRT in heart failure all
demonstrated a beneﬁt of CRT using simultaneous BiV pacing in
conjunction with AV delay optimization [3,5,7,9,10,44]. However,
it stands to reason that inter-individual variations in ventricular
conduction delay in diseased myocardium should affect the
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chronization, and this could be targeted to improve response to
CRT. Early hemodynamic data from 39 patients in the PATH-CHF
studies demonstrated similar improvements in left ventricular
contractile function (dP/dt) with either simultaneous BiV or
LV-only pacing [45]. In 41 patients from the same study population,
AV optimized simultaneous BiV or LV-only pacing resulted in
similar improvements in functional capacity and quality of life
that was sustained at 12-month follow-up [46]. This suggests that
the critical event in CRT is timing of left ventricular stimulation.
Other studies have demonstrated acute hemodynamic improve-
ments in invasively measured LV dP/dt with optimization of the
VV interval over nominal simultaneous BiV pacing, with signiﬁ-
cant variation of this interval between patients [24,47,48]. Several
noninvasive approaches to VV optimization have been proposed,
each with its own limitations.3.1. Dyssynchrony-guided VV optimization
As with AV optimization, VV optimization has most often been
performed with echocardiograpy in attempt to improve markers
of cardiac dyssynchrony. Patients may display evidence of both
inter- and intra-ventricular dyssynchrony, which are related but
slightly different entities. Inter-ventricular dyssynchrony results
from a delay in left ventricular contraction relative to right
ventricular contraction, and it can be quantiﬁed as the difference
in pre-ejection delay from the surface QRS to the onset of
pulmonic and aortic systolic ejection visualized with pulsed
Doppler echocardiography. Intra-ventricular dyssynchrony refers
to delay in segmental wall motion, which can be quantiﬁed using
LV septal to posterior wall motion delay, tissue Doppler imaging
(TDI), and strain rate analysis using a variety of metrics. Borda-
cher et al. [49] evaluated the effect of sequential VV pacing on
cardiac output (as measured by aortic VTI) and markers of inter-
and intra-ventricular dyssynchrony using pulsed Doppler and TDI
in 41 patients with CRT. They found that improvements in intra-
ventricular dyssynchrony correlated with an increase in cardiac
output, while changes in inter-ventricular dyssynchrony had no
correlation. Furthermore, simultaneous BiV pacing was the opti-
mal setting in only 15% of patients. This suggests that optimizing
the VV delay using TDI markers of dyssynchrony will result in
acute hemodynamic improvements over BiV pacing alone. Similar
ﬁndings of the acute improvement in intra-ventricular dyssyn-
chrony with sequential over simultaneous BiV pacing have been
reported [50]. However, a 6-month follow-up study of this
method of optimized sequential versus simultaneous pacing in
100 patients found now improvement in the rate of CRT respon-
ders [51].
More recently, Abraham et al. [52] reported the results of a
randomized study in 238 patients of simultaneous versus opti-
mized sequential BiV pacing. The VV interval was adjusted to
minimize the septal to posterior wall motion delay. At 6-month
follow-up, signiﬁcantly more patients had improved based on aTable 1
Summary of the various methods of AV and VV interval optimization.
AV optimization
Echocardiography Mitral inﬂow (Ritter method, iterative m
‘‘Fast and Simple’’) aortic VTI
Alternative techniques Impedance cardiography, ﬁnger photopl
acoustic cardiography, peak endocardial
Intracardiac electrogram-based
algorithms
Boston Scientiﬁc SmartDelayTM, St. Jude
QuickOptTM,
Medtronic Adaptive Algorithmclinical composite score with optimized sequential (75%) than
with simultaneous BiV pacing (65%). However, there were no
signiﬁcant differences in the 6-minute walk distances, quality of
life, or heart failure event rates. Importantly, 82% of patients in
the optimized group had a VV interval other than 0 ms.
VV optimization using echocardiographically derived markers
of dyssynchrony is signiﬁcantly limited by the time and expertise
required. For example, in the PROSPECT trial to evaluate the
predictive value of echocardiographic markers of dyssynchrony
for response to CRT, there was signiﬁcant variability in TDI quality
despite extensive training of study sites.[11] More telling was a
survey of AV/VV optimization practices at centers involved the
FREEDOM trial of the St. Jude QuickOptTM algorithm. The reported
use of TDI was only 13.6% among centers, which is likely an
overestimate of its use among practices worldwide [53]. Thus, the
applicability of dyssynchrony optimization in a ‘‘real-world’’
clinical setting is questionable.
3.2. Aortic VTI method
A simpliﬁed echocardiographic approach involves optimiza-
tion of the VV interval using aortic VTI, similar to AV delay
optimization. In this method, the aortic VTI is measured at
varying intervals of RV and LV preexcitation, and that producing
the highest VTI is used as the optimal VV delay. In a study of 34
patients by Mortensen et al. [54], VV optimization resulted in
higher aortic VTI in comparison to simultaneous BiV pacing,
although 3-month outcomes, as deﬁned by NYHA classiﬁcation
and 6-min walk distance, were similar among those who were or
were not optimized. The InSync III trial [15] compared the aortic
VTI method of VV optimization in 422 patients using the MIRACLE
[3] study population as the control group. They again demon-
strated signiﬁcant improvements in stroke volume and 6-min
walk distance with optimized VV pacing above simultaneous
pacing alone, but there was no signiﬁcant difference in improve-
ment in NYHA class or quality of life. Subsequent studies have
also failed to demonstrate an improvement in 6-month clinical
outcomes with aortic VTI optimized VV intervals over simulta-
neous BiV pacing.[55,56].
3.3. Other methods of VV optimization
Despite limited data demonstrating improved outcomes with
echocardiography-guided VV optimization, several other approaches
have been developed. These include real-time intracardiac echo-
cardiography during CRT implantation [57], electroanatomic
mapping [58], radionuclide angiography [59], the Finometers
[60], peak endocardial acceleration [30], and optimization using
the surface QRS [61,62]. Several device-based IEGM algorithms for
VV optimization have also been developed and evaluated
(Tables 1 and 2).
The St. Jude QuickOptTM algorithm (St. Jude Medical, Inc., St.
Paul, Minnesota, USA) calculates the optimal AV delay and VVVV optimization
ethod, LV M-mode (Septal-posterior wall motion delay),
tissue Doppler imaging, aortic VTI
ethysmography,
acceleration
Intracardiac echocardiography, electroanatomic mapping,
radionuclide angiography, ﬁnger photoplethysmography,
peak endocardial acceleration, surface ECG




Major Randomized Trials of CRT AV/VV Optimization
Major trials of AV/VV delay optimization
N Technique Result
Abraham et al. (FREEDOM)[74] 1525 Optimization at implant with standard of care vs.
QuickOptTM AV/VV optimization every 3 months
No difference in 12 month clinical composite score
Ellenbogen et al. (SMART-AV)[17] 980 Fixed AV delay (120 ms), iterative method,
or SmartDelayTM AV optimization
No difference in 6 month change in LVESV,
NYHA class, QOL, or 6 min walk
Martin et al. (adaptive CRT)[70] 522 Echo optimized AV/VV delays (iterative and aortic VTI) vs.
Adaptive CRT algorithm
Adaptive CRT noninferior to echo optimization
in clinical composite score (73.6 vs. 72.5% improved)
Ritter et al. (CLEAR)[30] 238 Standard of care optimization (mostly echo) vs.
PEA AV/VV optimization algorithm
Signiﬁcantly more improved in clinical composite
score with PEA vs. standard of care (76 vs. 62%)
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The AV delay is determined from the duration of the sensed atrial
electrogram: if 4100 ms, 30 ms is added to calculate the optimal
AV delay and if o100 ms, 60 ms is added. For the paced AV delay
offset, 50 ms is added to the sensed AV delay. The VV offset
determination is more complex. The time interval between
sensed local activation between the RV and LV leads is ﬁrst
measured (D). The difference in conduction delay to the RV lead
during LV pacing and LV lead during RV pacing is then calculated
(e). The estimated optimal VV offset is then given by the formula
VV¼0.5(Dþe), with positive values indicating left ventricular
preactivation and negative values indicating right ventricular
preactivation. This algorithm was initially evaluated in 11
patients and found to correlate well with the optimal VV delay
obtained using the aortic VTI method [63]. However, subsequent
validation studies have shown conﬂicting results, with some
demonstrating a good correlation with echocardiographically
optimized VV delays and others suggesting inferior performance
of the algorithm [64–67]. More importantly, there are no pro-
spective data on the effect of this algorithm on long-term clinical
outcomes.
Another IEGM-based algorithm utilized in Boston Scientiﬁc
devices has been evaluated as well. The optimal VV delay is
estimated using the formula VV¼0.33 (RVLV electrical
delay)—20 ms. This was derived from unpublished data from
PATH-CHF studies. The DECREASE-HF study prospectively rando-
mized 306 patients to a VV delay determined using this algo-
rithm, simultaneous BiV pacing, or LV pacing alone. At 3- and
6-month follow-up, all patients showed improvements in left
ventricular volumes, stroke volume, and ejection fraction. With
the exception of a greater decrease in left ventricular end-systolic
dimension with simultaneous pacing, there was no signiﬁcant
difference between groups [68]. As with the St. Jude’s Quick-
OptTM, there are no long-term clinical outcome data using this
algorithm.
A third IEGM-based algorithm developed by Medtronic (Med-
tronic, Inc., Minneapolis, Minnesota, USA) was recently evaluated
in the Adaptive CRT trial. The algorithm provides continuous
adjustment of the AV and VV intervals based on periodic mea-
surement of the intrinsic AV interval (as measured from the RA
and RV electrodes), the interval from the sensed atrial EGM to the
end of a far-ﬁeld P wave, and the interval from sensed RV EGM to
the end of a far-ﬁeld QRS complex. If the intrinsic AV interval is
o200 ms and the heart rate is o100 bpm, LV-only pacing is
provided at an AV delay to preempt intrinsic conduction by
440 ms. If the intrinsic AV interval is 4200 ms or the heart rate
4100 bpm, BiV pacing is provided at an AV delay that is longer
than the duration of the far-ﬁeld P wave but 450 ms prior to the
intrinsic RV sensed EGM. The VV offset is then determined
based on the intrinsic AV delay and interval from the sensed RV
EGM to the end of the QRS complex [69]. In Adaptive CRT, 522
patients were prospectively randomized to echocardiographicallyoptimized CRT or continuous optimization using the IEGM-based
algorithm. Aortic VTI correlated well at the optimal AV/VV
settings in both arms, and at 6 months, patients managed with
this algorithm had similar CRT response rates to those optimized
echocardiographically, with no difference in heart failure events.
Use of the algorithm also resulted in a 44% reduction in RV pacing
at 6 months. In the subset of patients with normal AV conduction
and LBBB, the algorithm resulted in more frequent LV-only pacing
and signiﬁcantly better response rates than echocardiographic
optimization. This suggests either nor beneﬁt or potential dele-
terious effects of LV offset with biventricular pacing [70]. These
data support the Adaptive algorithm as an alternative, noninferior
method of AV/VV optimization to echocardiography. However,
the study does not prove either optimization strategy superior to
empiric AV/VV delay programming.
3.4. Areas of uncertainty in VV optimization
It is evident that while VV optimization using the methods
available can improve the acute hemodynamic response of CRT,
long-term clinical improvement above that derived from simul-
taneous BiV pacing has not been deﬁnitively proven. There are
several possible explanations for this discrepancy in results. First,
the methods used for VV optimization may be suboptimal to
achieve adequate inter- and intra-ventricular resynchronization.
As previously discussed, the technical difﬁculty of Doppler opti-
mization methods introduces the possibility of operator error.
IEGM-based algorithms do not account for LV lead location, which
can inﬂuence the degree of preexcitation required for maximum
resynchronization [71]. An additional methodological concern
involves the sequence of AV and VV optimization. In almost all
studies of VV optimization, AV delay optimization was performed
ﬁrst followed by VV optimization. This utility of this strategy has
been questions by a study that determined the optimal AV/VV
settings by testing 45 different combinations of AV and VV
intervals. The optimal settings identiﬁed with this method were
signiﬁcantly different from a strategy of optimizing the AV or VV
interval ﬁrst [72].
Second, the magnitude of hemodynamic improvement with
optimized VV pacing may be too small to be clinically meaningful.
In the study by Mortensen et al. [54], for example, sequential
pacing signiﬁcantly increased stroke volume by 20% in compar-
ison to simultaneous pacing, but the absolute increase was
relatively small (12 mL). This may not be sufﬁcient to result in
measurable differences in clinical outcomes.
Third, it is has been repeatedly shown that the optimal VV
delay, like the AV delay, varies over time [36,37,54,56] and with
exertion [73]. Programming a ﬁxed, though optimized VV interval
at the time of implantation would then be similar to empiric
programming at long-term follow-up. The FREEDOM trial
attempted to address this problem by randomizing 1067 patients
to routine CRT management or AV and VV optimization every
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observed difference in the response rates to CRT between the
two management strategies [74]. As discussed previously, the
Medtronic Adaptive IEGM-based algorithm provides virtually
continuous AV/VV optimization, and it resulted in outcomes that
were noninferior to ﬁxed, though optimized AV/VV intervals [70].
While these studies suggest that frequent AV/VV adjustment
offers no beneﬁt over optimization at implant, it is possible
that the algorithms used were inadequate. It remains to be
seen if continuous, hemodynamically optimized CRT could prove
beneﬁcial.
Finally, it may be that VV optimization has been applied to the
wrong population of patients. The majority of CRT recipients
appear to beneﬁt from biventricular or left ventricular pacing,
particularly in the presence of a LBBB. Whereas VV optimization
may not improve response rates in an unselected population of
CRT patients, focused application in patients with a suboptimal
response or non-LBBB morphologies could potentially be bene-
ﬁcial. This question was addressed in a study of 65 patients
identiﬁed as ‘‘non-responders’’ who were randomized to simulta-
neous BiV pacing or VV optimization. Response rates were 18.9%
higher at 9 month follow-up in the optimized group, although this
difference was not statistically signiﬁcant and 50% of patients in
the control group became responders [75].4. Conclusions
CRT non-responder rates have remained relatively stable
despite attempts to improve patient selection and programming
optimization. Many different methods for AV and VV delay
optimization have been developed, and all have demonstrated
that optimized delays, regardless of the method, result in acute
improvements in LV diastolic and systolic function. These func-
tional improvements have unfortunately not consistently trans-
lated into improvements in clinical outcomes or response rates to
CRT. As routine AV delay optimization was performed in most
trials demonstrating efﬁcacy of CRT, it is a reasonable strategy
that does not appear to be harmful. More recent data suggest,
however, that an empiric AV delay of 120 ms is not inferior to
available optimization methods. Moreover, 3 large multicenter
trials (FREEDOM, SMART AV, and ADAPTIVE CRT) failed to show
superiority of IEGM-based optimization over nominal settings or
echo techniques. This has led to the evaluation of other techni-
ques for improving CRT outcome, such as placing LV leads in
locations of late mechanical [76] or electrical activation [77].
Current techniques and available data make routine VV optimiza-
tion impractical and unnecessary in the majority of patients.
At the present time, the beneﬁt of routine use of AV and VV
interval optimization is unclear and may be most useful in the
population of CRT ‘‘non-responders,’’ although the beneﬁt of this
strategy also requires further study.Conﬂict of interest
None.
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